BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Biotech Beach

  ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

  ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) today announced topline results from its clinical study comparing repeat doses of neffy (epinephrine nasal spray) to repeat doses of epinephrine intramuscular (IM) injection, as requested by the FDA with and without nasal allergen challenge (NAC) conditions.

  February 20, 2024

   · 

  13 min read
• IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries

  IR-MED Inc. reported highly favorable proof of efficacy data for PressureSafe™, its decision support device which uses infra-red spectroscopy combined with an AI-based algorithm, for the early, non-invasive, and skin color agnostic detection of pressure injuries.

  February 20, 2024

   · 

  7 min read
• BioForest

  Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

  Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

  February 20, 2024

   · 

  4 min read
• Business

  Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

  Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.

  February 20, 2024

   · 

  1 min read
• Lone Star Bio

  FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

  FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”) is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials.

  February 20, 2024

   · 

  6 min read
• Job Trends

  Lilly to Participate in Cowen’s 44th Annual Health Care Conference

  Eli Lilly and Company (NYSE: LLY) will participate in Cowen’s 44th Annual Health Care Conference on March 6, 2024.

  February 20, 2024

   · 

  1 min read
• Business

  GT Medical Technologies, Inc. Names Per Langoe As CEO

  GT Medical Technologies, Inc. today announced that Per Langoe, a proven industry leader with in-depth radiation oncology experience has joined the company as CEO.

  February 20, 2024

   · 

  3 min read
• Biotech Bay

  Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

  Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”) today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

  February 20, 2024

   · 

  12 min read
• Pharm Country

  Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

  Cyclacel Pharmaceuticals, Inc. today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.

  February 20, 2024

   · 

  3 min read
• Business

  OcuSciences Welcomes Michael Patane, PhD, to its Board of Directors

  OcuSciences today announced the addition of Michael Patane, PhD, to its Board of Directors.

  February 20, 2024

   · 

  2 min read